Black checkmark with a sparkle and a curved line underneath on a white background.
Company

KORU Medical Systems, Inc.

Ticker
KRMD
Sector
Industry
Report date
November 10, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments include quarterly earnings calls and reports highlighting revenue growth, narrowing losses, reaffirmed guidance, and regulatory certifications such as EU MDR for the Freedom60 infusion pump.

Recent developments:
  • KORU reported Q2 2026 earnings and revenues above prior expectations, with detailed earnings call transcripts and highlights available [N1][N2][N3].
  • In Q1 2026, the company reported a narrowing net loss alongside revenue growth and reaffirmed its full-year 2026 guidance [N4][N5][N6].
  • KORU secured EU MDR certification for its Freedom60 infusion pump, supporting its regulatory compliance and market access in Europe [N1].
Overview

KORU Medical Systems, Inc. specializes in large volume subcutaneous infusion solutions designed for patient self-administration and healthcare professional use. Its core product platform, the FREEDOM Infusion System, includes syringe drivers, safety needle sets, and precision tubing, enabling delivery of immunoglobulin and other subcutaneous drugs. The company operates primarily in the US and international markets, selling through distributors, specialty pharmacies, and home infusion providers. KORU supports biopharmaceutical companies with clinical trial services and product customization. The company emphasizes innovation, regulatory compliance, and expanding market penetration in the subcutaneous immunoglobulin (SCIg) market and emerging subcutaneous therapies. Manufacturing is partly in-house and partly outsourced. KORU faces regulatory and supply risks inherent to medical device and drug delivery markets.

Executive summary

KORU Medical Systems, Inc. develops and commercializes large volume subcutaneous infusion systems primarily for immunoglobulin therapies treating diseases such as Primary Immunodeficiency Diseases and Chronic Inflammatory Demyelinating Polyneuropathy. The company generates revenue from domestic and international sales of its FREEDOM Infusion Systems and from pharma services related to clinical trials. The FREEDOM System is FDA cleared and certified internationally for multiple on-label indications and is the market leader in the US for SCIg delivery. As of September 30, 2026, KORU reported quarterly revenues of $11.57 million and net income of $218,103, with strong liquidity ratios. The company invests in research and development and maintains manufacturing operations in New Jersey and Nicaragua. Recent earnings calls and news highlight revenue growth, narrowing losses, reaffirmed guidance, and regulatory certifications. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for KRMD

Bull case model:

KORU Medical Systems benefits from increasing diagnoses of immunodeficiency diseases and expanding indications for subcutaneous immunoglobulin therapies, supporting demand for its FREEDOM System. The company’s focus on innovation and regulatory approvals enables it to extend its product platform into emerging subcutaneous drug therapies beyond SCIg. Its partnerships with biopharmaceutical companies during clinical development generate non-recurring engineering revenues and position it for commercialization opportunities. Strong liquidity and improving operating income reflect operational progress. The company’s market leadership and channel relationships support continued penetration in domestic and international markets.

Bear case model:

KORU Medical Systems faces risks related to dependence on the availability of drugs administered via its devices, including potential supply disruptions or changes in drug indications that could reduce demand. Competition from alternative therapies and delivery devices may erode market share. The company must successfully introduce new products and keep pace with technological advances to avoid obsolescence. Regulatory changes or delays in obtaining clearances could impact commercialization. Concentration of sales through a limited number of distributors may pose risks. Manufacturing and supply chain dependencies on single-source suppliers could affect product availability.

Moat:

KORU Medical Systems' moat is anchored in its FDA-cleared and internationally certified FREEDOM Infusion System, which is the market-leading delivery system for subcutaneous immunoglobulin therapies in the US. The company's integrated system of syringe drivers, safety needle sets, and precision tubing is designed for ease of use, portability, and maintenance-free operation, differentiating it from electrical pumps. Its established relationships with pharmaceutical companies, specialty pharmacies, and distributors provide channel access and support for clinical trial collaborations and product customization. Regulatory clearances and ongoing innovation contribute to barriers for competitors. The company's manufacturing capabilities and regulatory expertise further support its competitive position.

Risks overview
Risks summary
The biggest risks for KORU Medical Systems relate to dependence on drug supply availability, regulatory challenges, competition from alternative therapies, and the need to innovate and maintain product relevance.
Risks details:

• Dependence on Drug Supply: The company’s products require availability of immunoglobulin therapies and other drugs. Disruptions in drug supply or changes in FDA indications could reduce demand for KORU’s devices.
• Regulatory and Compliance Risks: KORU’s devices are subject to FDA and international regulatory requirements. Delays or failures in obtaining clearances or changes in regulations could impact product commercialization.
• Competitive Risks: Emerging alternative therapies and delivery devices may compete with KORU’s products, potentially reducing market share and revenues.
• Product Development Risks: Failure to successfully develop and introduce new products or adapt to technological changes could render existing products obsolete and harm financial performance.
• Supply Chain Risks: Reliance on single-source suppliers and contract manufacturers for components and consumables may affect the company’s ability to meet customer demand timely.

FINAL FORECAST FOR KRMD

Final take one line
KORU Medical Systems exhibits high visibility through detailed SEC disclosures and recent earnings communications highlighting its leadership in subcutaneous infusion systems and ongoing operational progress.
Final take 12 to 24 month view

Business trends: Increasing diagnoses of immunodeficiency diseases and expanding subcutaneous therapy indications drive demand; growing biopharmaceutical partnerships support clinical and commercial product use.
Execution milestones: Regulatory certifications including FDA and EU MDR clearances; quarterly revenue growth and narrowing losses; ongoing R&D investments and product innovation.
Key risks: Dependence on drug supply availability and regulatory approvals; competition from alternative therapies; need for successful product development and supply chain reliability.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • KORU Medical Systems, Inc. develops, manufactures, and commercializes large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market, focusing on mechanical infusion products called the FREEDOM Infusion Systems.
  • The FREEDOM System includes the FREEDOM60 Syringe Driver, FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets, and Precision Flow Rate Tubing.
  • The company generates revenues from three sources: domestic core (US and Canada), international core, and pharma services and clinical trials.
  • Core revenues come from sales of syringe drivers, tubing, and needles for subcutaneous drugs cleared by the FDA, mainly for immunoglobulin treatments for Primary Immunodeficiency Diseases (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
  • Pharma services and clinical trials revenues include product revenue for feasibility and clinical trials of biopharmaceutical companies and non-recurring engineering services to customize the FREEDOM System for clinical and commercial use.
  • The FREEDOM System is FDA 510(k) cleared and certified outside the US for delivery of several on-label subcutaneous indications including Cutaquig, Cuvitru, Hizentra, Xembify, Empaveli, and Gammagard Liquid.
  • The system is also FDA approved for administration of RYSTIGGO for generalized myasthenia (gMG).
  • The FREEDOM System is portable, easy to operate, maintenance free, and does not require batteries or electricity, operating at lower pressure than electrical pumps.
  • The company sells products through direct sales and medical device distributors to pharmaceutical companies, specialty pharmacies, and home infusion providers, with a small number of distributors accounting for a large portion of revenues.
  • Manufacturing is done 100% in-house for pump products at Mahwah, NJ, and partially outsourced for consumables to Command Medical Products in Nicaragua.
  • The company invests in research and development, spending $4.4 million in 2025 and $5.3 million in 2024, focusing on infusion pumps, consumables, and accessories.
  • KORU Medical is subject to FDA and other regulatory requirements governing development, testing, manufacturing, labeling, marketing, and distribution of medical devices.
  • As of September 30, 2026, the company reported $11.57 million in revenue for the quarter and $35.38 million for the nine months ended, with a net income of $218,103 for the quarter.
  • Liquidity ratios as of 2026-09-30 include a current ratio of 2.97 and a cash ratio of 1.08, with cash and cash equivalents of approximately $7.36 million.
  • The company reported a net operating income of $187,118 for Q3 2026, improving from a loss in the prior year period.
  • The company reaffirmed its FY26 guidance and reported narrowing net losses in Q1 2026 with revenue growth.
  • Recent news includes Q2 2026 earnings call transcripts and highlights, reporting earnings and revenues above prior expectations, and EU MDR certification for the Freedom60 infusion pump.
  • The company is focused on expanding its leadership in the subcutaneous immunoglobulin (SCIg) market and extending into emerging subcutaneous drug therapies.
  • Key market trends include increasing diagnoses of PIDD, expansion of SCIg indications, growth in SCIg treatment options, ongoing biopharmaceutical investment in SCIg therapies, increasing availability of donated plasma, and patient preference for at-home SCIg therapy.
  • The company aims to partner with biopharmaceutical manufacturers during clinical development to customize products and obtain regulatory clearance, then commercialize products post-launch.
  • The FREEDOM System remains the market-leading delivery system in the US for SCIg treatments.
  • The company faces risks including dependence on drug supply availability, regulatory changes, competition from alternative therapies, and the need to successfully introduce new products and keep pace with technology advances.
Sources
Sources - Context summary

Generated 2026-11-11

Sources - Earning calls
  • N1
  • N2
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-12 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-08-12 | www.nasdaq.com | KORU (KRMD) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/koru-krmd-q2-2026-earnings-call-transcript
  • N2 | 2026-08-06 | www.nasdaq.com | KORU Medical Systems Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/koru-medical-systems-q2-earnings-call-highlights
  • N3 | 2026-08-05 | www.nasdaq.com | KORU Medical Systems, Inc. (KRMD) Q2 Earnings and Revenues Beat Estimates | https://www.nasdaq.com/articles/koru-medical-systems-inc-krmd-q2-earnings-and-revenues-beat-estimates
  • N4 | 2026-05-07 | www.nasdaq.com | KORU Medical Systems Q1 Net Loss Narrows On Revenue Growth; Reaffirms FY26 Guidance; Stock Up | https://www.nasdaq.com/articles/koru-medical-systems-q1-net-loss-narrows-revenue-growth-reaffirms-fy26-guidance-stock
  • N5 | 2026-05-07 | www.nasdaq.com | Koru Medical (KRMD) Q1 2026 Earnings Transcript | https://www.nasdaq.com/articles/koru-medical-krmd-q1-2026-earnings-transcript
  • N6 | 2026-05-06 | www.nasdaq.com | KORU Medical Systems, Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/koru-medical-systems-inc-krmd-reports-q1-loss-tops-revenue-estimates
  • N7 | 2026-05-06 | www.nasdaq.com | American Well Corporation (AMWL) Reports Q1 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/american-well-corporation-amwl-reports-q1-loss-tops-revenue-estimates
  • N8 | 2026-05-04 | www.nasdaq.com | Inspire Medical Systems (INSP) Q1 Earnings and Revenues Top Estimates | https://www.nasdaq.com/articles/inspire-medical-systems-insp-q1-earnings-and-revenues-top-estimates
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine